President Donald Trump announced that all 50 states, Washington, DC, and Puerto Rico will participate in a new Medicaid drug pricing model in which manufacturers provide supplemental rebates to align Medicaid net prices. The policy is described as moving toward “most favored nation” pricing across participating jurisdictions, with the change tied to broader federal implementation plans and state participation.